China has emerged as a credible challenger to the US in artificial intelligence-driven drug discovery, where advantage depends not only on computing prowess but also on the ability to effectively mine data, from genomes to clinical trial results, according to Leung Chuen-yan, a private equity investor and life sciences scientist.
“Globally, the way companies develop and use AI to discover drugs is similar, from finding the drug target and designing the molecule to planning clinical trials,” said…
China challenges US in AI drug race, but rivals still reliant on each other
